Cargando…

Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy

BACKGROUND: Duchenne Muscular Dystrophy is a severe, incurable disorder caused by mutations in the dystrophin gene. The disease is characterized by decreased muscle function, impaired muscle regeneration and increased inflammation. In a clinical context, muscle deterioration, is evaluated using phys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strandberg, Kristin, Ayoglu, Burcu, Roos, Andreas, Reza, Mojgan, Niks, Erik, Signorelli, Mirko, Fasterius, Erik, Pontén, Fredrik, Lochmüller, Hanns, Domingos, Joana, Ala, Pierpaolo, Muntoni, Francesco, Aartsma-Rus, Annemieke, Spitali, Pietro, Nilsson, Peter, Szigyarto, Cristina Al-Khalili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2020
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369103/ https://www.ncbi.nlm.nih.gov/pubmed/32390640 http://dx.doi.org/10.3233/JND-190454

Ejemplares similares

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
por: Signorelli, Mirko, et al.
Publicado: (2019)

Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
por: Johansson, Camilla, et al.
Publicado: (2023)

Tracking disease progression non‐invasively in Duchenne and Becker muscular dystrophies
por: Spitali, Pietro, et al.
Publicado: (2018)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models
por: Tsonaka, Roula, et al.
Publicado: (2020)

Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies
por: Ayoglu, Burcu, et al.
Publicado: (2014)

Biomarkers of Duchenne muscular dystrophy: current findings
por: Szigyarto, Cristina Al-Khalili, et al.
Publicado: (2018)

TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy
por: Spitali, Pietro, et al.
Publicado: (2020)

Multiomic characterization of disease progression in mice lacking dystrophin
por: Signorelli, Mirko, et al.
Publicado: (2023)

Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne
por: Lourbakos, A., et al.
Publicado: (2017)

Rimeporide as a ﬁrst- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy
por: Previtali, Stefano C., et al.
Publicado: (2020)

The importance of genetic diagnosis for Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2016)

Analysis of public RNA-sequencing data reveals biological consequences of genetic heterogeneity in cell line populations
por: Fasterius, Erik, et al.
Publicado: (2018)

Penalized regression calibration: A method for the prediction of survival outcomes using complex longitudinal and high‐dimensional data
por: Signorelli, Mirko, et al.
Publicado: (2021)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Imperatives for DUCHENNE MD: a Simplified Guide to Comprehensive Care for Duchenne Muscular Dystrophy
por: Kinnett, Kathi, et al.
Publicado: (2015)

Spatial transcriptomics reveal markers of histopathological changes in Duchenne muscular dystrophy mouse models
por: Heezen, L.G.M., et al.
Publicado: (2023)

Single-cell RNA-seq variant analysis for exploration of genetic heterogeneity in cancer
por: Fasterius, Erik, et al.
Publicado: (2019)

Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2019)

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants
por: van den Bergen, Janneke C, et al.
Publicado: (2015)

The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012)

Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy
por: Passarelli, Chiara, et al.
Publicado: (2020)

The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2007)

Quantifying the burden of caregiving in Duchenne muscular dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2016)

CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies
por: Chey, Yu C. J., et al.
Publicado: (2022)

Compliance to Care Guidelines for Duchenne Muscular Dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2015)

Case Report: The Genetic Diagnosis of Duchenne Muscular Dystrophy in the Middle East
por: Alghamdi, Fouad, et al.
Publicado: (2021)

DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials
por: Muntoni, Francesco, et al.
Publicado: (2023)

Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the mdx Mouse Model for Duchenne Muscular Dystrophy
por: Engelbeen, Sarah, et al.
Publicado: (2021)

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
por: Landfeldt, Erik, et al.
Publicado: (2016)

Plasma lipidomic analysis shows a disease progression signature in mdx mice
por: Tsonaka, Roula, et al.
Publicado: (2021)

Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
por: Doorenweerd, Nathalie, et al.
Publicado: (2017)

Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy
por: Meng, Jinhong, et al.
Publicado: (2016)

The burden of Duchenne muscular dystrophy: An international, cross-sectional study
por: Landfeldt, Erik, et al.
Publicado: (2014)

Author Correction: Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
por: Doorenweerd, Nathalie, et al.
Publicado: (2018)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures
por: Hiller, Monika, et al.
Publicado: (2018)

Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
por: Rodger, Sunil, et al.
Publicado: (2012)

Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis
por: Landfeldt, Erik, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kaifl8vqut26kgqctau0uaojl2